Skip to main content

Advertisement

SpringerLink
Log in

Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany

  • Global Perspectives: Original Research
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Background

Japan is currently the second largest pharmaceutical market in the world, and Japanese pharmaceutical companies are actively seeking to identify assets in other countries. An affluent population provides ample opportunity for pharmaceutical companies to develop within Japan; however, given its weak macroeconomic foundation, Japan is currently seeking to cut costs through the use of more generic drugs and lower prices. Nevertheless, no detailed empirical analyses regarding how Japanese companies can expand their global presence while ensuring domestic sales, or what opportunities lie ahead for global companies planning to enter the Japanese market, have been conducted. To our knowledge, this is the first study to provide statistical evidence regarding characteristics of the Japanese market.

Methods

The data set for this study was the most recent list of the 100 top-selling drugs globally and in Japan, the United States, the United Kingdom, France, and Germany. The data were obtained from the IMS Japan Pharmaceutical Market database.

Results

More cardiovascular and less central nervous system (CNS) and oncology drugs were ranked among the top 100 best-selling drugs in the Japanese market; however, the promotion of CNS and oncology drug development was evident, and competition from generic drugs was shown to have eroded, especially in therapeutic areas with no assured benefits in the global market, such as with cardiovascular drugs.

Conclusions

These results suggest that the Japanese market will rival overseas markets in the near future. Pharmaceutical companies should seriously consider operating within Japan, whose market is currently transitioning to a global market.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Glenn Thomas Lacy. Are we all global now? Local vs. foreign sources of corporate competence: the case of the Japanese pharmaceutical industry. Strategic Manage J. 2004:25:865–886.

    Article  Google Scholar 

  2. Shibata S, Uemura R, Suzuki T. Factors that affect acquisition of reward premiums for promotion of innovative drug discovery in Japan. Ther Innov Regul Sci. (in press)

  3. Cegedim Strategic Data K.K. Global Pharmaceuticals Sales Ranking in 2013. June 2014. Osaka, Japan: Cegedim Strategic Data K.K.

    Google Scholar 

  4. Riku J. Current situation for generic drugs in Japan. J Generic Med. 2005;2:219–231.

    Article  Google Scholar 

  5. Shimura H, Masuda S, Kimura H. Analyzing the generic penetration trend in the Japanese dispensing market by therapeutic category. J Generic Med. 2012;9:55–62.

    Article  Google Scholar 

  6. Chabner BA. Drug shortages—a critical challenge for the generic-drug market. N Engl J Med. 2011;365:2147–2149.

    Article  CAS  Google Scholar 

  7. Dickson M, Gagnon JP. The cost of new drug discovery and development. Discov Med. 2009;4:172–179.

    Google Scholar 

  8. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87:272–277.

    Article  Google Scholar 

  9. Kola I. The state of innovation in drug development. Clin Pharmacol Ther. 2008:83:227–230.

    Article  CAS  Google Scholar 

  10. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–716.

    Article  CAS  Google Scholar 

  11. LaMattina JL. The impact of mergers on pharmaceutical R&D. Nat Rev Drug Discov. 2011;10:559–560.

    Article  Google Scholar 

  12. Barnes JJ, Cohen R, Cardoo EJ. Microcosms in aquatic ecosystem research. In: Hemingway E, ed. Pollution and Aquatic Ecosystems. Springfield, VA: National Technical Information Service; 1986:24–39.

    Google Scholar 

  13. Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin K. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther. 2008;15:450–457.

    Article  Google Scholar 

  14. IMS Health Inc. IMS Health Market Prognosis, June 2013. Danbury, CT: IMS Health Inc.

    Google Scholar 

  15. Umemura M, Fujioka R. Comparative responses to globalization experiences of British and Japanese Enterprises. New York: Palgrave Macmillan; 2013.

    Book  Google Scholar 

  16. IMS Health Inc. MAT pharmaceutical market statistical analysis in 2014. Danbury, CT: IMS Health Inc.

  17. Takaku F, Yazaki Y. Manual of Therapeutic Agents 2014. Tokyo, Japan: Igaku-Shoin Ltd; 2014.

    Google Scholar 

  18. Braun MM, Farag-El-Massah S, Xu K, Coté TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev. 2010;9:519–522.

    CAS  Google Scholar 

  19. Miller BA, Chu KC, Hankey BF, Ries LAG. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the US. Cancer Causes Control. 2008;19:227–256.

    Article  Google Scholar 

  20. Shibata S, Uemura R, Suzuki T. Impact of premium rewards for the promotion of innovative drug discovery on the Japanese pharmaceutical market: an analysis by therapeutic area. Therap Innovation Regul Sci. (in press)

  21. World Health Organization. Asia Pacific strategy for emerging diseases (2005).

  22. Lansang MA, Alejandra M, Banzon E, Castillo-Carandang N, Juban N. A rapid situational analysis of health policy and systems research in the Western Pacific region. World Health Organization, Western Pacific Regional Office, 2006.

Download references

Author information

Authors and Affiliations

  1. Division of Basic Biological Sciences Faculty of Pharmacy, Keio University, 1-5-30 Shibakoen, Minato-ku, Tokyo, 8512, Japan

    Shoyo Shibata RPh & Takeshi Suzuki RPh, PhD

  2. Division of Basic Education, Faculty of Pharmacy, Keio University, Tokyo, Japan

    Ryotaro Uemura PhD

Authors
  1. Shoyo Shibata RPh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryotaro Uemura PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takeshi Suzuki RPh, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Suzuki RPh, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shibata, S., Uemura, R. & Suzuki, T. Comparative Analysis Between the Top-Selling Drugs in the Japanese Pharmaceutical Market and Those in the United States, the United Kingdom, France, and Germany. Ther Innov Regul Sci 50, 221–227 (2016). https://doi.org/10.1177/2168479015604182

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479015604182

Keywords

Search

Navigation